Best for Inflammation and immune-signaling research
Inflammation claims range from compounds with clinical-trial histories to peptides supported only by cellular or animal models. This page ranks the public source record by human evidence, regulatory history, and reproducibility rather than by popularity. It does not provide treatment or purchasing guidance.
Thymosin Alpha-1
The deepest clinical record in this group, including more than 100 registered studies and approval in multiple countries outside the United States.
Evidence level: Human clinical-trial record with international regulatory use
Regulatory status: Approved in multiple countries; not FDA-approved in the United States
Thymosin Alpha-1 has been studied across infectious-disease, oncology, and immune-modulation settings and is marketed as thymalfasin in multiple countries. Its clinical literature is broader than the other peptides on this page, but it is not FDA-approved in the United States.
LL-37
A well-characterized human antimicrobial peptide with substantial laboratory literature but no approved therapeutic product in the United States.
Evidence level: Substantial peer-reviewed laboratory evidence; limited clinical evidence
Regulatory status: Not FDA-approved; regulatory watch
LL-37 has broad antimicrobial and immune-signaling activity in laboratory studies. Its biology is complex: the peptide participates in host defense but is also implicated in inflammatory and autoimmune pathways. Clinical development remains limited and no FDA-approved LL-37 treatment exists.
KPV
A focused anti-inflammatory peptide signal in animal and cellular models, without published human efficacy trials.
Evidence level: Preclinical only
Regulatory status: Not FDA-approved; regulatory watch
KPV is a short alpha-MSH-derived peptide studied for anti-inflammatory activity in preclinical models. Public claims frequently move from animal findings to broad human-use conclusions that the available evidence does not support.
BPC-157
High public attention for inflammatory and recovery claims despite a thin human research record and active regulatory scrutiny.
Evidence level: Predominantly preclinical and public discussion
Regulatory status: Not FDA-approved; regulatory watch
BPC-157 is frequently described online as anti-inflammatory and tissue-protective, but the public human trial record is extremely limited. FDA materials place the compound within ongoing compounding and safety review, and marketing claims should not substitute for clinical evidence.
TB-500
Commonly grouped with recovery and inflammation protocols online, but supported primarily by mechanistic extrapolation from thymosin beta-4 research.
Evidence level: Preclinical and mechanistic extrapolation
Regulatory status: Not FDA-approved; regulatory watch
TB-500 marketing often borrows from broader thymosin beta-4 literature. Product-specific clinical evidence is not established, and the compound remains outside FDA approval with active regulatory review considerations.
Immune modulation can create both benefit and harm. Preclinical anti-inflammatory findings do not establish safety or efficacy in humans, and none of the research-use-only products discussed here are FDA-approved for general inflammation treatment.
Source records are stored in the repo and linked from this page.
ClinicalTrials.gov registry search showing 100+ interventional studies of thymosin alpha-1 across infectious disease, oncology, and immune support contexts, including COVID-19 trials.
King R, Tuthill C (2016) comprehensive review (PMID 26653168) of thymosin alpha-1's immune-modulating mechanism, clinical development history, and therapeutic applications including hepatitis, oncology, and sepsis.
SciClone Pharmaceuticals product information for Zadaxin (thymosin alpha-1), approved in over 30 countries for chronic hepatitis B, hepatitis C, and immune adjuvant use. Not FDA-approved in the United States.
Dürr UHN, Sudheendra US, Ramamoorthy A (2006) foundational review (PMID 16459200) of LL-37 structure, mechanism, broad-spectrum antimicrobial activity, and role as the sole human cathelicidin.
Kahlenberg JM, Kaplan MJ (2013) review (PMID 23836012) of LL-37's dual role in innate immunity and autoimmunity, describing both protective antimicrobial effects and pro-inflammatory potential in autoimmune disease.
ClinicalTrials.gov registry search for interventional studies involving LL-37/cathelicidin, showing limited clinical trial activity. LL-37 is not FDA-approved for any indication.
Preclinical studies of KPV (Lys-Pro-Val), a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH), showing anti-inflammatory effects in animal models of intestinal and systemic inflammation. No human clinical trials have been published.
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.